The research, led by Chunhong Li of The Second Affiliated Hospital of Guilin Medical University, together with Xin Zeng and Yuhua Mao, addresses a stubborn gap in environmental health science. While epidemiological studies have suggested links between endocrine-disrupting chemicals and breast cancer, the precise molecular mechanisms through which MEP exposure might drive oncogenesis and tumor progression have remained poorly understood. Laboratory work in model systems has added to the concern: recent studies have shown that methylparaben can induce metabolic disorder and liver damage at human-relevant exposure levels, disrupt endocrine function and impair reproduction in adult zebrafish, and correlate with altered semen quality in reproductive-aged men. Meanwhile, Mendelian randomization analyses combined with network toxicology have begun to suggest causal relationships between the compound and cancers including glioblastoma and breast cancer. What has been missing is a systematic, integrated picture of how MEP’s molecular targets intersect with the genomic and immunological landscape of actual breast tumors.

To build that picture, the team assembled breast cancer-related targets from three authoritative disease databases: the Comparative Toxicogenomics Database, GeneCards, and OMIM. On the chemical side, they interrogated MEP-related targets from ChEMBL, PharmMapper, and the Similarity Ensemble Approach, applying stringent filters to ensure that only high-confidence chemical-protein associations survived. The intersection of these two target sets formed the seed of the analysis, informing the construction of protein-protein interaction networks designed to reveal which human proteins sit at the crossroads of MEP’s toxicological activity and breast cancer biology. Molecular docking studies then tested, at the structural level, whether MEP could plausibly bind the key proteins identified by the network analysis, providing a physical rationale for the computational associations.

The results converged on five core putative toxicological targets that appear to play critical regulatory roles in MEP-associated molecular alterations: HSP90AA1, CTNNB1, TP53, MYC, and EGFR. For anyone familiar with cancer biology, this list reads like a hall of fame of oncogenic machinery. HSP90AA1 encodes the molecular chaperone HSP90, which stabilizes hundreds of client proteins and has been independently implicated in breast cancer progression and doxorubicin resistance through PI3K/AKT signaling; elevated plasma HSP90AA1 has even been proposed as a predictor of breast cancer onset and distant metastasis. CTNNB1 encodes beta-catenin, the transcriptional co-activator at the heart of the Wnt signaling pathway, which has recently become the target of novel covalent degrader drugs. TP53, the guardian of the genome, shapes long-term responses to CDK4/6 inhibitors in breast cancer through its role in cellular senescence. MYC, the archetypal oncogenic transcription factor, has been shown to suppress STING-dependent innate immunity in triple-negative breast cancer. And EGFR acts as what researchers have called a master switch between immunosuppressive and immunoactive tumor microenvironments in inflammatory breast cancer.

That a single cosmetic preservative would dock onto and potentially modulate this particular quintet of proteins is the study’s most striking finding, because it suggests a plausible mechanistic route by which chronic, low-level MEP exposure could touch some of the most fundamental circuits of tumor biology: chaperone stabilization of oncogenic clients, Wnt-driven proliferation, loss of genomic surveillance, immune evasion, and growth factor signaling. The authors are careful to frame these as putative targets identified through computational inference rather than proven causal agents, but the convergence of network toxicology, docking evidence, and prior experimental literature on each of these proteins gives the hypothesis a weight that few single-method studies could muster.

But the team did not stop at target identification. In a second major analytical phase, they derived consensus molecular subtypes of breast cancer by applying ten different clustering algorithms to multi-omics data from patient cohorts, drawing on datasets from The Cancer Genome Atlas, UCSC XENA, and the GEO repositories. This consensus clustering approach, implemented through purpose-built R packages for multi-omics integration, guards against the well-known problem that any single clustering method can impose artificial structure on high-dimensional data. By requiring agreement across ten algorithms, the researchers aimed to identify molecular subgroups of breast cancer that reflect genuine biological differences rather than statistical artifacts. These consensus subtypes then served as the foundation for the study’s most clinically oriented deliverable.

Using three machine learning algorithms applied to the subtype-classified multi-omics data, the researchers developed what they call a consensus MEP-related signature, abbreviated CMEPRS, a prognostic model for breast cancer patients. The signature functions as a molecular classifier that stratifies patients according to the activity of MEP-toxicity-related genes in their tumors. In essence, the model asks not whether a patient was exposed to methylparaben, but whether the molecular programs that MEP is predicted to perturb are active in that patient’s tumor, and whether that activity pattern carries prognostic information. The resulting classifiers and the CMEPRS prognostic model, the authors report, may facilitate patient stratification and support personalized clinical management, offering oncologists a new computational lens through which to view tumor biology that is rooted in environmental toxicology rather than conventional pathological categories.

The immunological findings that emerged from applying the signature are particularly provocative. Patients with high CMEPRS scores displayed prominent infiltration of macrophages, myeloid-derived suppressor cells, and cancer-associated fibroblasts, three cell types that collectively form the cellular architecture of an immunosuppressive tumor microenvironment. This triad is familiar to immunotherapy researchers for an unwelcome reason: tumors dominated by these populations tend to exclude cytotoxic T cells and resist checkpoint blockade. The finding resonates with established literature showing that EGFR can act as a switch governing whether the inflammatory breast cancer microenvironment is immunosuppressive or immunoactive, and that MYC can suppress innate immune sensing in triple-negative disease. In other words, the MEP-associated molecular signature appears to mark tumors whose microenvironmental composition would be expected to blunt immunotherapy response, a hypothesis that could be tested directly in future clinical studies.

Drug sensitivity predictions added a further layer of translational interest. Using computational tools that predict in vivo drug response from cell line screening data, the team found that, apart from the HER2-targeted drug lapatinib, high-CMEPRS patients showed higher predicted sensitivity to most conventional chemotherapeutic drugs. If validated, this pattern would carry practical implications: the MEP-associated molecular state might not only flag a more immunosuppressive and prognostically distinct tumor, but also one that could be managed effectively with existing cytotoxic regimens, while raising questions about the relative benefit of specific targeted agents. The study’s authors emphasize that their work is computational and therefore preliminary, providing insights into molecular alterations linked to MEP exposure rather than definitive proof of harm or clinical utility.

Nevertheless, the broader significance of the study lies as much in its methodology as in its specific findings. By fusing network toxicology with multi-omics consensus clustering and machine learning, the researchers have demonstrated a feasible analytical framework for connecting environmental chemical exposure to cancer patient stratification and therapeutic-target exploration, a template that could be applied to the dozens of other endocrine-disrupting chemicals that populate modern life. As global breast cancer incidence continues to climb across 185 countries, and as recent commentary in leading cancer journals urges a rethinking of the origins of early-onset estrogen receptor-positive disease in light of environmental endocrine disruptors, studies of this kind sharpen the questions that laboratory and epidemiological work must now answer. Whether methylparaben truly helps set the stage for breast cancer will require experimental validation, but this research has mapped, with unusual precision, exactly where to look.

Subject of Research: Computational analysis of molecular mechanisms linking the endocrine-disrupting preservative methyl 4-hydroxybenzoate to breast cancer

Article Title: Integrated multi-omics, machine learning, network toxicology, and molecular docking reveal potential mechanisms underlying methyl 4-hydroxybenzoate-associated breast cancer

Article References: Integrated multi-omics, machine learning, network toxicology, and molecular docking reveal potential mechanisms underlying methyl 4-hydroxybenzoate-associated breast cancer. (n.d.). https://doi.org/10.1007/s11030-026-11712-1

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11712-1

Keywords: breast cancer, methylparaben, endocrine-disrupting chemicals, network toxicology, molecular docking, multi-omics, machine learning, prognostic signature, tumor microenvironment, HSP90AA1, TP53, EGFR

Diffuse large B-cell lymphoma, or DLBCL, is the most frequent subtype of non-Hodgkin lymphoma, accounting for approximately 30 to 40 percent of all cases. For two decades, the frontline standard of care was R-CHOP, a five-drug immunochemotherapy combining the monoclonal antibody rituximab with three chemotherapeutic agents and a corticosteroid. Despite countless attempts to improve upon it with novel agents, R-CHOP remained essentially unchallenged until the POLARIX trial demonstrated that swapping vincristine for polatuzumab vedotin—a targeted antibody-drug conjugate directed against CD79b, a signaling component of the B-cell receptor—produced significantly superior outcomes. That result transformed Pola-R-CHP into the new global standard for previously untreated DLBCL, and the regimen was approved in China in April 2023 for adult patients.

Yet the POLARIX trial enrolled only patients with international prognostic index scores of 2 through 5, meaning patients considered to have intermediate or high-risk disease. The IPI is a well-established scoring system that predicts prognosis in DLBCL using five factors: age, tumor stage, number of extranodal sites involved, performance status, and serum lactate dehydrogenase levels. Patients scoring 0 or 1 are conventionally labeled low-risk and represent approximately 30 percent of newly diagnosed cases. Because they were excluded from the pivotal trial, this substantial population became a critical evidence gap. The problem is compounded by the fact that low IPI scores do not guarantee biological simplicity. Many of these patients carry molecular and pathological features known to undermine standard therapy, including bulky tumors, double-expressor lymphoma, and abnormalities of the TP53 gene, the so-called guardian of the genome.

The new study, led by Yuhong Ren and Peng Liu of Zhongshan Hospital, Fudan University, together with colleagues across China, set out to fill that gap using real-world data. Between June 2023 and July 2025, the researchers enrolled 118 consecutive previously untreated DLBCL patients with IPI scores of 0 or 1 who received at least one cycle of Pola-R-CHP. The median age was 53.5 years, with patients ranging from 17 to 87 years old. Despite their formally low-risk classification, the cohort was biologically heterogeneous and carried a surprising burden of adverse features: 51.7 percent had the non-germinal center B-cell-like subtype, 24.6 percent had double-expressor lymphoma, 9.3 percent had double-hit or triple-hit lymphoma, 25.4 percent showed high P53 expression, 12.7 percent had bulky disease, and 62.7 percent had extranodal involvement.

The treatment protocol followed a well-defined structure. Each 21-day cycle comprised polatuzumab vedotin at 1.8 milligrams per kilogram of body weight, rituximab at 375 milligrams per square meter, cyclophosphamide at 750 milligrams per square meter, doxorubicin at 50 milligrams per square meter or epirubicin at 70 milligrams per square meter, and prednisone at 100 milligrams orally for five consecutive days. Patients received a median of six cycles. Efficacy was assessed using whole-body fluorodeoxyglucose PET/CT or contrast-enhanced CT imaging after three to four cycles and again at the end of treatment, with responses graded according to the 2014 Lugano classification, the international standard for lymphoma response assessment.

The results were remarkable. Among the 68 patients who had completed end-of-treatment evaluation at the data cut-off of August 2025, 63 achieved a complete response, yielding a complete response rate of 92.6 percent. The overall response rate reached 98.5 percent at end of treatment and 98.9 percent at interim assessment, with 78.2 percent of interim-evaluated patients already in complete remission after just three to four cycles. Only two patients experienced disease progression during follow-up, both of whom had central nervous system involvement, and no deaths occurred at a median follow-up of 7.1 months. Importantly, the 50 patients without end-of-treatment assessment had not progressed, died, or been lost to follow-up; they were simply still undergoing treatment or awaiting imaging, meaning the missing data reflected short follow-up rather than treatment failure.

Perhaps most striking was the consistency of responses across molecular subgroups. Exploratory analyses showed broadly similar response rates at both interim and end-of-treatment time points among elderly patients, those with the non-germinal center subtype, extranodal disease, double-expressor lymphoma, and double-hit or triple-hit lymphoma. The one exception was the high P53 expression subgroup, where the complete response rate was numerically lower at 78.6 percent compared with 96.9 percent in patients with low or absent P53 expression. This finding aligns with the well-documented biology of TP53 alterations, which are associated with genomic instability and chemoresistance in lymphoma. However, the researchers caution that the small number of evaluable patients in this subgroup prevents definitive conclusions, and they suggest that the bystander effect of antibody-drug conjugates—the ability of the drug payload to diffuse into neighboring tumor cells that may not express the target antigen—could theoretically help overcome the clonal heterogeneity that drives resistance.

Safety data from all 118 patients showed a tolerable profile without unexpected toxicity compared with the POLARIX trial. Any grade 3 or 4 adverse event occurred in 24.6 percent of patients. The most common adverse events overall were anemia in 68.6 percent, leukopenia in 47.5 percent, and decreased neutrophil count in 39.8 percent, the vast majority of which were mild to moderate. The most frequent severe toxicity was neutropenia, affecting 21.2 percent of patients at grade 3 or 4—a manageable side effect routinely addressed with dose adjustments and growth factor support in clinical practice. No new safety signals emerged, reinforcing the regimen’s established risk-benefit profile in a broader and more diverse population than the original trial captured.

The study’s authors place their findings in context by comparing them with other real-world cohorts and historical R-CHOP data. Published complete response rates for frontline Pola-R-CHP and R-CHOP in low-risk patients range from 80.6 to 96.5 percent, and the current results sit comfortably at the upper end of that spectrum. Notably, the Chinese cohort carried a heavier burden of adverse features than a comparable R-CHOP cohort from a Chinese phase 3 trial, with higher rates of impaired performance status, advanced stage disease, and double-expressor lymphoma, yet still achieved outstanding responses. The researchers acknowledge the inherent limitations of a retrospective, single-arm design conducted exclusively in China, including potential selection bias and immature survival data, and they emphasize that a conservative sensitivity analysis counting all unevaluated patients as non-responders still yielded a complete response rate of 85.1 percent.

The implications reach beyond the numbers. Roughly a third of DLBCL patients worldwide fall into the IPI 0-1 category, yet they remain underrepresented in clinical trials and continue to experience late relapses even in limited-stage disease, a pattern that contrasts with the survival plateau seen in advanced-stage patients. This study provides the first multicenter real-world evidence that Pola-R-CHP is both effective and tolerable in this population, even when adverse biological features are present. The authors call for prospective randomized trials to precisely define the magnitude of benefit, and for molecular subtyping strategies to better identify which low-risk patients harbor hidden resistance mechanisms. For now, the message for clinicians is clear: the antibody-drug conjugate revolution in lymphoma treatment appears to extend to nearly every patient who walks through the door, not just those who fit the narrow criteria of a registration trial.

Subject of Research: Frontline Pola-R-CHP treatment of low-risk diffuse large B-cell lymphoma

Article Title: Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in China

Article References: Ren, Y., Liu, J., Lin, Z., Shou, L., Zeng, H., Wu, D., Zeng, Z., Zhou, F., Bao, L., Jing, H., Jiang, S., Liu, H., Shen, J., Yu, W., Zhou, H., Xu, J., Zhang, Y., Wang, T., Huang, H., … Liu, P. (2026). Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in China. Clinical Cancer Bulletin, 5(1), Article 21. https://doi.org/10.1007/s44272-026-00073-3

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00073-3

Keywords: diffuse large B-cell lymphoma, Pola-R-CHP, polatuzumab vedotin, antibody-drug conjugate, international prognostic index, real-world study, R-CHOP, double-expressor lymphoma, TP53, complete response, non-Hodgkin lymphoma, immunochemotherapy

The clinical backdrop makes the advance urgent. Gastric cancer remains one of the world’s deadliest malignancies, characterized by molecular heterogeneity, a high propensity for metastatic spread, and frequent therapeutic resistance. Immune checkpoint blockade, particularly antibodies against the PD-1/PD-L1 axis, has transformed outcomes in several tumor types, yet in gastric cancer the response rates stubbornly remain below 30 percent, with a substantial fraction of patients showing intrinsic resistance from the very first dose. The researchers turned to cancer genetics for an explanation. A significant subset of gastric cancers, especially those defined by chromosomal instability, carry two simultaneous alterations: loss of the tumor suppressor TP53 and hyperactivation of YAP, the transcriptional co-activator that serves as the main effector of the Hippo signaling pathway. YAP1 is amplified in roughly 18 percent of human gastric cancers, and the combination of YAP activation with p53 loss correlates clinically with aggressive, refractory disease. Whether this genetic pairing was a mere correlation or a true causal driver of immunotherapy resistance was the central question the study set out to answer.

To probe that question, the investigators engineered a sophisticated mouse model they call AYP. These animals carry a conditional, constitutively active YAP1 mutant, designated Yap1-6A, in which six phosphorylation sites were mutated so the protein resists degradation, together with floxed Tp53 alleles. Both alterations were activated specifically in the Atp4b-expressing parietal cell lineage of the stomach, which encompasses parietal cell progenitors, pre-parietal cells, and mature acid-producing cells. After tamoxifen induction, the mice developed invasive gastric adenocarcinoma within two to three months, with a median survival of 131 days. Crucially, the model demonstrated biological synergy rather than mere additivity: mice with YAP activation alone or p53 loss alone failed to develop gastric cancer even ten months after induction, while the double-hit configuration produced fully penetrant, aggressive malignancy. Histopathological examination revealed the full spectrum of human disease, including well-differentiated intestinal-type tumors, poorly differentiated signet-ring cell carcinomas of the diffuse type, and mixed forms, all accompanied by dense immune infiltration.

The metastatic behavior of the model proved equally faithful to the human condition. By three to four months after induction, the majority of AYP mice had disseminated disease involving the gastric lymph node, diaphragm, liver, pancreas, mediastinal lymph node, and lung, with metastatic incidence rates recorded for each organ across the cohort. Fluorescent labeling confirmed that the metastatic lesions originated from the Atp4b-lineage tumor cells. When the researchers treated these mice with anti-PD-1 antibodies for three weeks, the results were sobering but clinically familiar: stomach weights were unchanged, metastatic incidence and morphology were unaltered, and histopathology confirmed no therapeutic response. Immune profiling showed only a modest reduction in neutrophils, regulatory T cells, and group 3 innate lymphoid cells. In other words, the AYP tumors were intrinsically resistant to PD-1 blockade despite being what immunologists would call hot tumors, densely infiltrated with immune cells that should, in principle, be attackable.

To find the mechanism, the team performed single-cell RNA sequencing on nearly 50,000 high-quality cells harvested from the stomach, gastric lymph node, and visible liver and lung metastases of AYP mice and matched wild-type controls. The analysis identified three distinct tumor cell clusters, and gene set variation analysis revealed strong enrichment of Hippo signaling, YAP/TAZ target gene signatures, epithelial-mesenchymal transition features, and immunosuppression programs. When the researchers compared the mouse tumor transcriptomes with a single-cell dataset from 26 gastric cancer patients, the AYP tumor cells correlated closely with human poorly differentiated gastric adenocarcinoma, including signet-ring cell carcinoma, with high correlation coefficients for signature genes such as OLFM4, PLA2G2A, and ENO1. A dominant feature of the microenvironment, at both primary and metastatic sites, was a pronounced infiltration of neutrophils displaying characteristics of polymorphonuclear myeloid-derived suppressor cells, key systemic mediators of immunosuppression that are clinically associated with poor immunotherapy responses. Depleting neutrophils substantially inhibited tumor development and metastasis, establishing these cells as essential players rather than bystanders.

The search for the molecular bridge between YAP and the suppressive microenvironment converged on BST2, or bone marrow stromal cell antigen 2. Integrated analysis of tumor cell signature genes and genes downregulated after YAP1 knockout identified BST2 as a top candidate. Immunofluorescence confirmed that BST2 was co-expressed with the tumor marker KRT7 specifically within tumor tissue and was undetectable in normal gastric epithelium. Clinically, the pattern was striking: both BST2 and YAP1 transcription were markedly higher in gastric cancer patients whose disease progressed on anti-PD-1 therapy than in those achieving complete or partial responses, mirroring established immunosuppressive markers such as NR4A1 and CD55. Mechanistically, the team showed that deleting YAP1 with CRISPR/Cas9 significantly reduced both BST2 mRNA and surface protein levels, and CUT&RUN assays demonstrated direct binding of the YAP1-TEAD4 transcriptional complex to the Bst2 promoter, formally establishing BST2 as a direct YAP target gene.

Functional experiments then revealed BST2 as a genuine immune checkpoint operating on innate immune cells. Deleting BST2 from AYP tumor cells had only a marginal effect on proliferation in a dish but significantly impaired tumor formation and growth in living mice, accompanied by reduced numbers of tumor-infiltrating neutrophils and lower PD-L1 expression on those cells, decreased exhaustion of natural killer and CD4 T cells, and increased production of the cytotoxic enzyme Granzyme B. Ligand-receptor interaction analysis pointed to BST2 engaging a receptor called PIRA2, the murine ortholog of human leukocyte immunoglobulin-like receptors, which is highly expressed on neutrophils. Co-immunoprecipitation and protein truncation experiments mapped the physical interface: the coiled-coil domain of BST2 directly binds the Ig-like domain of PIRA2 through two distinct contact surfaces. Co-culture assays confirmed that AYP tumor cells drive bone marrow cells toward an immunosuppressive SiglecF-positive, PD-L1-positive neutrophil phenotype, an effect abolished either by BST2 knockout or by a BST2-blocking antibody.

The liver emerged as a particularly instructive battleground. Kupffer cells, the resident macrophages of the liver, also express high levels of PIRA2, and transcriptional profiling showed that AYP mice accumulated immunosuppressive Kupffer cell subsets at the expense of immunostimulatory ones. In co-culture, AYP tumor cells expanded the pool of CD11b-high Kupffer cells and upregulated the suppressive markers Arg1 and PD-L1, effects again dependent on BST2. In a liver metastasis model based on splenic injection of tumor cells, BST2 deficiency significantly prolonged host survival, reduced metastatic tumor burden, and boosted Granzyme B production by liver CD8 T cells, indicating reinvigorated anti-tumor immunity. The therapeutic culmination came in the spontaneous AYP model itself: combining anti-BST2 with anti-PD-1 antibodies reduced stomach weights by nearly 30 percent compared with anti-PD-1 alone, restored glandular tissue architecture, and, most strikingly, completely eradicated visible liver metastases in all treated animals while suppressing lymph node spread beyond what either agent achieved alone.

The implications reach beyond gastric cancer. BST2 was upregulated in tumors from resistant patients across multiple cancer types, suggesting it may function as a pan-tumor marker of anti-PD-1 failure, and its known role in suppressing plasmacytoid dendritic cells offers a plausible explanation for how anti-BST2 therapy also curbed lymph node metastases. The study also raises tantalizing questions about the microbial dimension, since bacteria such as Helicobacter pylori and Streptococcus anginosus can activate YAP signaling in gastric epithelium, potentially sustaining the BST2-driven resistance program. Significant work remains before patients benefit: the downstream signaling events of BST2-PIRA2 engagement are not fully mapped, structural studies of the interaction are needed to design high-affinity blockers, and humanized anti-BST2 antibodies must now prove themselves in patient-derived models. Still, for the large population of patients whose hot, immune-infiltrated gastric tumors inexplicably shrug off PD-1 blockade, the identification of a druggable YAP-BST2 axis offers something they have not had before: a mechanistic explanation and a concrete combination strategy to test in the clinic.

Subject of Research: YAP-BST2-mediated intrinsic resistance to anti-PD-1 immunotherapy in metastatic gastric cancer

Article Title: Targeting the YAP‐BST2 Axis Overcomes Intrinsic Anti‐PD‐1 Resistance in Metastatic Gastric Cancer

Article References: Zhang, W., Wang, S., Wang, M., Yu, R., Yue, J., Shao, L., Zhang, H., Zhu, M., Tian, L., Cheng, S., Qin, W., Tang, Y., Han, Y., Wang, W., An, L., Meng, Y., Jiao, S., & Zhou, Z. (2026). Targeting the YAP‐BST2 Axis Overcomes Intrinsic Anti‐PD‐1 Resistance in Metastatic Gastric Cancer. Advanced Science, Article e77708. https://doi.org/10.1002/advs.77708

Image Credits: AI Generated

DOI: 10.1002/advs.77708

Keywords: gastric cancer, immunotherapy resistance, YAP, TP53, BST2, PD-1, neutrophils, Kupffer cells, PIRA2, Hippo pathway, mouse model, liver metastasis

The research, led by Cédric Poyet of Stadtspital Triemli in Zurich and Marie Lork of the University Hospital of Zurich, together with colleagues from Kantonsspital Baden, Luzerner Kantonsspital and University Hospital Zurich, set out to identify molecular correlates of overall survival in muscle-invasive bladder cancer, often abbreviated MIBC. The team analyzed tumor DNA extracted from cystectomy specimens, the surgical samples obtained when the bladder is removed, from 32 patients treated at Swiss centers. The study received ethical approval from the Cantonal Ethics Committee Zurich and was conducted in accordance with the Declaration of Helsinki.

To characterize the genomic landscape of each tumor, the investigators used the FoundationOne CDx comprehensive genomic profiling platform, a targeted next-generation sequencing assay capable of detecting substitutions, insertions and deletions, copy number alterations and selected genomic instability markers across hundreds of cancer-related genes. Patients were then divided into two comparison groups based on a hard clinical endpoint: a favorable outcome group of 14 patients who survived at least 60 months after surgery, and a poor outcome group of 18 patients who survived fewer than 60 months. This dichotomy allowed the researchers to ask a simple but clinically vital question: which genomic features separate long-term survivors from those who die earlier of their disease?

Across the entire cohort, the sequencing effort uncovered 279 pathogenic or likely pathogenic mutations distributed across 88 genes. The most frequently altered genes were familiar names in bladder cancer biology: TP53, the guardian-of-the-genome tumor suppressor whose inactivation is a near-universal event in this disease; PIK3CA, a signaling kinase driving PI3K pathway activation; KDM6A, a histone demethylase involved in chromatin regulation; and FGFR3, a receptor tyrosine kinase that is a well-established oncogenic driver and drug target in urothelial carcinoma. Perhaps surprisingly, the distributions of these frequent alterations were similar between the favorable and poor outcome groups, indicating that the presence or absence of these canonical mutations alone does not explain the dramatic survival differences observed in the clinic.

The team next turned to the standard quantitative indicators of genomic instability that have been proposed as prognostic and predictive biomarkers in many tumor types. Tumor mutational burden, or TMB, reflects the total number of somatic mutations carried by a tumor and is widely used as a proxy for responsiveness to immune checkpoint inhibitors. Microsatellite instability, or MSI, marks defects in DNA mismatch repair and carries prognostic and predictive significance in colorectal and several other cancers. In this MIBC cohort, however, both metrics were comparable between the long-term survivors and the poor outcome group, and neither proved prognostically informative. The finding is a caution against assuming that biomarkers validated in other cancers will translate directly to bladder cancer.

The decisive signal emerged from a different layer of genomic complexity: copy number alterations. Tumors from the poor outcome group exhibited a significantly higher frequency and burden of gene amplifications, events in which segments of DNA containing particular genes are copied multiple times, often massively, driving overexpression of the encoded proteins. Crucially, these amplifications frequently involved known oncogenes and co-amplification hotspots, regions of the genome where neighboring growth-promoting genes are gained together in a single event. In other words, patients whose tumors carried a heavy load of oncogene amplifications were disproportionately represented among those who died within five years of cystectomy.

The biological logic behind this observation is compelling. While point mutations typically disable tumor suppressors or alter the function of a single protein, amplifications act as gene dosage escalators, flooding tumor cells with growth factor receptors, signaling kinases and cell cycle accelerators. High-level amplification of oncogenes can simultaneously promote proliferation, survival under therapeutic stress and metastatic competence. Moreover, co-amplification events can deliver several oncogenic payloads at once, creating tumors that are intrinsically more aggressive and harder to eradicate with a single targeted agent. The Swiss findings suggest that this dosage-driven mode of tumor evolution may be a hallmark of the most lethal forms of MIBC.

The results also carry therapeutic implications. Amplified oncogenes are, in principle, druggable targets. FGFR inhibitors are already approved for metastatic urothelial carcinoma in tumors with FGFR alterations, and agents directed against amplified receptor kinases and downstream signaling nodes are in clinical development across many cancer types. If the association between amplification burden and poor survival is confirmed, comprehensive copy number profiling at the time of cystectomy could help identify patients who warrant intensified treatment, such as perioperative systemic therapy escalation, enrollment in targeted therapy trials or closer surveillance for recurrence. Conversely, the lack of prognostic value for TMB and MSI in this cohort suggests that these markers should not be relied upon in isolation for outcome prediction in MIBC.

The authors are careful to frame the study as exploratory, and the caveats are substantial. The cohort comprised only 32 patients, divided into groups of 14 and 18, a sample size that limits statistical power and leaves open the possibility of confounding by clinical factors such as stage, nodal status and treatment sequence, which the abstract does not address in detail. The use of a targeted panel, while broad, does not capture the full spectrum of structural variants and noncoding alterations that whole-genome sequencing would reveal. The authors explicitly call for validation in larger cohorts to determine whether oncogene amplifications can serve as robust prognostic markers and to explore their potential as therapeutic targets. It is also worth noting that Roche funded the genomic testing through the FoundationOne CDx platform but had no role in study design, data analysis, interpretation or manuscript writing, apart from being granted the opportunity to review the manuscript prior to submission.

Even with these limitations, the study adds an important dimension to the ongoing effort to bring precision oncology to bladder cancer. The field has long focused on the mutational catalog of urothelial carcinoma, one of the most heavily mutated of all common tumors, yet this work suggests that the architecture of copy number gains may carry at least as much prognostic weight as the mutation list itself. For patients facing cystectomy, a procedure with significant morbidity and a five-year survival that remains unsatisfactory for many, any molecular signal that reliably separates indolent from lethal disease is valuable. If larger studies confirm that oncogene amplification burden predicts poor overall survival, clinicians may one day sequence not just for mutations but for the sheer number of oncogene copies a tumor carries, using that information to triage patients toward more aggressive, and hopefully more effective, treatment strategies from the moment of diagnosis.

Subject of Research: Genomic profiling of oncogene amplifications as prognostic markers of overall survival in muscle-invasive bladder cancer

Article Title: Oncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC)

Article References: Poyet, C., Franzen, A. S., Bieri, U., Kaufmann, E., Eberli, D., Schmid, M., Zoche, M., Moch, H., & Lork, M. (2026). Oncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC). Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06626-2

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06626-2

Keywords: muscle-invasive bladder cancer, oncogene amplifications, genomic profiling, tumor mutational burden, microsatellite instability, TP53, FGFR3, PIK3CA, copy number alterations, prognostic biomarkers, cystectomy, FoundationOne CDx

The study, led by Emily L. Podany and Andrew A. Davis of Washington University in St. Louis together with collaborators at Weill Cornell Medicine, Northwestern University, and Massachusetts General Hospital, drew on clinical and genomic data collected between 2015 and 2024. All patients had metastatic breast cancer and had undergone liquid biopsy testing with the Guardant360 assay, which detects mutations, copy number changes, and gene fusions across dozens of cancer-related genes from a simple blood sample. To quantify neighborhood disadvantage, the team used the Area Deprivation Index, or ADI, a validated composite of seventeen measures including poverty, employment, and education, ranked nationally from 1 to 100 by nine-digit zip code. Patients scoring 60 or above were classified as living in high deprivation neighborhoods.

Of the 1,127 patients analyzed, 335, or 29.7 percent, lived in high deprivation areas. Black patients were more than three times as likely as White patients to reside in these neighborhoods, reflecting the deep entanglement of race and socioeconomic disadvantage in the United States. After adjusting for age, race, cancer subtype, sites of metastatic disease, treatment line, and other clinical variables, the researchers found that patients from high deprivation neighborhoods had roughly 49 percent higher odds of harboring TP53 mutations in their tumors. Conversely, they were significantly less likely to carry AKT1 mutations, an alteration typically enriched in slower-growing, lower-grade luminal tumors.

The TP53 gene encodes p53, often described as the guardian of the genome. In healthy cells, this tumor suppressor protein halts division when DNA is damaged, triggers repair mechanisms, and pushes irreparably damaged cells into programmed death. When TP53 is mutated, that safety net collapses, allowing abnormal cells to proliferate unchecked. Mutations in the gene appear in roughly 30 percent of breast cancers and are linked to higher tumor grade, more aggressive subtypes, and worse prognosis. The new findings echo earlier tissue-based studies that connected household income and socioeconomic deprivation to higher p53 mutation frequency, but they extend that evidence to a large, racially diverse cohort of metastatic patients using blood-based genomic profiling.

Intriguingly, patients in high deprivation neighborhoods were less likely to present with visceral, lymph node, or soft tissue metastases, which might ordinarily suggest less advanced disease. Yet their survival was shorter. The authors propose that TP53-mutated tumors may drive rapid, aggressive progression even at lower disease burden, potentially before the kind of metastatic crises that prompt urgent intervention. They also point to the compounding weight of social determinants of health: patients in deprived neighborhoods experience higher rates of food insecurity, sarcopenia, and chronic disease, all of which erode the physical resilience needed to tolerate intensive cancer treatment.

The study also uncovered a stark treatment gap. Among 136 patients with hormone receptor-positive, HER2-negative metastatic disease who carried activating PIK3CA mutations and were therefore eligible for PI3K inhibitor therapy, only 17.4 percent of those in high deprivation neighborhoods actually received the drugs, compared with 36.7 percent of patients in low deprivation areas. This disparity emerged despite equal rates of PIK3CA mutations across deprivation groups, meaning the biological eligibility for targeted therapy was the same. The gap points squarely at access, not biology, as the limiting factor.

PI3K inhibitors such as alpelisib, approved by the Food and Drug Administration in 2019, and related AKT pathway inhibitors such as capivasertib represent some of the most consequential advances in precision oncology for breast cancer. But these therapies are expensive, require genomic testing to identify eligible mutations, and are often available primarily at academic cancer centers concentrated in affluent regions. Prior research has shown that patients from disadvantaged neighborhoods travel longer distances for care, are less likely to enroll in clinical trials, more often lack private insurance, and experience longer treatment delays and higher rates of therapy discontinuation. The new data suggest these structural barriers now extend into the era of molecularly targeted medicine.

Survival differences were perhaps the most sobering result. Median overall survival from the time of circulating tumor DNA testing was 24 months for patients in high deprivation neighborhoods versus 28 months for those in low deprivation areas, a statistically significant difference. When the researchers stratified by race, the picture became even more stark: Black patients in high deprivation neighborhoods survived a median of just 15 months, compared with 25 months for Black patients in low deprivation areas and 28 months for White patients regardless of neighborhood. Notably, Black patients living in advantaged neighborhoods fared as well as White patients, indicating that neighborhood deprivation and race interact to produce the worst outcomes rather than race acting alone.

The authors caution that the study has limitations. All patients were treated at large academic medical centers, so the findings may not generalize to community hospitals or rural clinics. The Area Deprivation Index has been criticized for overemphasizing housing values, and a single time-point measure cannot capture the cumulative environmental exposures involved in carcinogenesis, which unfolds over years or decades. Because the analysis was exploratory, no correction for multiple statistical testing was applied. Still, the cohort’s geographic breadth, spanning catchment areas across multiple states, and its use of individual-level chart review and uniform genomic testing lend considerable strength to the conclusions.

The implications reach beyond oncology. If living in a deprived neighborhood is associated with a distinct mutational landscape in metastatic tumors, then environmental stressors, chronic inflammation, and social adversity may be biologically embedded in cancer in ways that precision medicine alone cannot undo. The research team calls for laboratory studies of environmental exposures, epidemiological work on molecular subtypes by deprivation, and implementation science aimed at dismantling barriers to targeted therapy access. The team also plans structured patient interviews to understand precisely why eligible patients in high deprivation areas miss out on PI3K inhibitors. In the meantime, the study stands as a molecular argument that zip code should not determine tumor biology, treatment, or survival, and that closing the gap will require intervening on the neighborhoods themselves, not just the cancers within them.

Subject of Research: Associations between neighborhood deprivation and breast cancer tumor genomics, targeted treatment use, and survival in metastatic breast cancer patients

Article Title: Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival

Article References: Podany, E. L., Foffano, L., Gerratana, L., Medford, A. J., Heater, N. K., Nicolò, E., Tapiavala, S., Pontolillo, L., Putur, A., Jaber, D. A., Clifton, K., Katakam, N., Addison, S., Lipsyc-Sharf, M., Reduzzi, C., Ademuyiwa, F. O., Puglisi, F., Gradishar, W. J., Ma, C. X., … Davis, A. A. (2026). Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival. Breast Cancer Research and Treatment, 219(2), Article 5. https://doi.org/10.1007/s10549-026-08068-3

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08068-3

Keywords: breast cancer, neighborhood deprivation, Area Deprivation Index, TP53, circulating tumor DNA, PI3K inhibitors, health disparities, precision oncology, metastatic breast cancer, survival, social determinants of health, liquid biopsy

Lung cancer remains the most commonly diagnosed and deadliest malignant tumor worldwide, and while radical surgical resection is the treatment of choice for early-stage disease, postoperative recurrence continues to undermine long-term outcomes for a substantial fraction of patients. The clinical dilemma is familiar to every thoracic oncologist: two patients with seemingly identical tumor stage and histology can follow radically different trajectories after surgery, one remaining disease-free for a decade, the other relapsing within a year. Traditional staging, based on tumor size, nodal involvement and metastatic status, captures only part of this biological heterogeneity. The Shanghai team set out to determine whether the mutational landscape of resected tumors could close that gap, systematically delineating the gene mutation profile of a large real-world Chinese cohort and assessing the predictive value of critical mutations for postoperative disease-free survival (DFS).

The methodology was comprehensive. All 1,674 enrolled patients, treated between long follow-up windows and retrospectively identified from clinical records, had undergone NGS-based molecular profiling of their resected tumor specimens. The investigators collected detailed clinicopathological data, treatment information and survival outcomes, then constructed mutation profiles for the overall population and for clinically relevant subgroups. Statistical machinery included Kaplan-Meier survival curves to visualize differences in disease-free survival, univariate and multivariate Cox proportional-hazards regression to isolate the independent contribution of each genetic and clinical variable, and co-mutation analysis to test whether pairs of altered genes interact to shape prognosis more than either alteration alone.

The mutational census that emerged was broad: 144 relevant mutated genes were detected across the cohort, and the team mapped their frequencies across the population. Two alterations dominated the landscape. EGFR, the epidermal growth factor receptor gene long known to be unusually frequent in East Asian lung cancer populations, was mutated in 61.2 percent of patients, while TP53, the canonical guardian-of-the-genome tumor suppressor, was altered in 31.9 percent. The high EGFR prevalence itself underscores why population-specific genomic studies matter; mutation frequencies observed in predominantly Western cohorts do not simply translate to Chinese patients, and treatment guidelines built on foreign data risk misaligning with the biology of the patients they are meant to serve.

The prognostic signal, however, came less from EGFR than from a set of other genes. Univariate analysis revealed that patients harboring mutations in TP53, KRAS, MET, ROS1 or CDKN2A experienced significantly shorter disease-free survival than patients without those alterations. In contrast, and perhaps counterintuitively, ERBB2 mutations were associated with longer DFS, a finding that held up when the investigators pushed the data through multivariate modeling. That final model, which adjusted for confounders simultaneously, confirmed TP53 mutation, ERBB2 mutation, tumor and nodal stage (T/N classification) and pleural invasion as independent prognostic factors for postoperative disease-free survival. In other words, even after accounting for how advanced a tumor appeared anatomically, the mutational status of these genes carried genuine, standalone predictive information about whether a patient’s cancer would return.

The most consequential result concerned gene pairs. When the team performed co-mutation analysis, patients whose tumors carried both TP53 and MET mutations had the poorest prognosis of any molecular subgroup, with disease-free survival significantly worse than that of patients carrying either single mutation and dramatically worse than those wild-type for both genes. This synergistic worsening of outcome is biologically plausible: TP53 loss disables apoptotic safeguards and genomic integrity checks, while MET activation drives invasive growth and metastatic signaling pathways, and the combination may equip residual micrometastatic disease with a particularly aggressive phenotype. Critically, the TP53-MET co-mutation signal remained consistent when the analysis was repeated in the subgroup of patients whose disease did progress, reinforcing the robustness of the association rather than reflecting a statistical artifact of the full cohort.

For clinical practice, the implications are tangible. Postoperative risk stratification for lung cancer currently leans heavily on pathological stage, with adjuvant therapy decisions guided largely by nodal status and tumor size. This study provides evidence that NGS profiling of resected specimens can refine that stratification: a patient with a TP53-mutant tumor, or worse, a TP53 and MET co-mutant tumor, could be flagged for intensified surveillance imaging, consideration of adjuvant targeted therapy or chemotherapy trials, and earlier detection of recurrence through molecular monitoring. Conversely, an ERBB2-mutant patient with otherwise favorable anatomy may face a lower recurrence risk than staging alone would suggest, information that could spare unnecessary treatment toxicity. The authors explicitly frame the results as a reliable molecular basis for postoperative risk stratification and individualized adjuvant therapy in lung cancer.

The study’s scale and design give its conclusions unusual weight. Retrospective cohort studies of this kind are vulnerable to selection bias and to the vagaries of heterogeneous treatment patterns, but a sample of 1,674 consecutively sequenced patients with long-term follow-up is rare in the literature on resected lung cancer, and the concordance between univariate, multivariate and co-mutation analyses, together with validation in the progression subgroup, argues that the signals are genuine properties of the disease rather than artifacts. The work was approved by the Ethics Committee and Institutional Review Board of Shanghai Chest Hospital under reference number LS1808, conducted in line with the Declaration of Helsinki, and supported by the National Natural Science Foundation of China and the Chinese Society of Clinical Oncology. Corresponding authors Zhi-qiang Gao, Jun Lu and Bao-hui Han led the effort, with Feng Pan and Liang Zheng contributing equally as first authors.

What remains to be established is prospective validation. Retrospective association, however robust, must ultimately be tested in trials that assign adjuvant treatment based on mutational profile and measure whether outcomes improve; ongoing studies of adjuvant targeted therapy in EGFR-mutant disease suggest this paradigm is already moving into the clinic. The Shanghai data add momentum by identifying which patients, within the large EGFR-mutated population, are most and least likely to benefit from closer surveillance. As NGS testing becomes routine and cheaper for resected lung cancer specimens, studies like this one chart the path from genomic description to genomic prognosis, where every surgical specimen yields not just a diagnosis but a personalized forecast, and where the risk of recurrence, lung cancer’s most feared late event, can be anticipated and countered before the first recurrent cell ever shows up on a scan.

Subject of Research: Postoperative gene mutations as prognostic predictors of disease-free survival in Chinese patients with resected lung cancer

Article Title: Relationship between postoperative gene mutation and prognosis in chinese patients with lung cancer: a long-term follow-up retrospective cohort study

Article References: Pan, F., Zheng, L., Zhang, L.-L., Wang, X., Lu, A.-T., Zhou, C., Gao, Z.-Q., Lu, J., & Han, B.-H. (2026). Relationship between postoperative gene mutation and prognosis in chinese patients with lung cancer: a long-term follow-up retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16960-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16960-w

Keywords: lung cancer, gene mutation, TP53, EGFR, MET, disease-free survival, next-generation sequencing, postoperative recurrence, prognostic factors, co-mutation, retrospective cohort study, adjuvant therapy